157 related articles for article (PubMed ID: 37717359)
1. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
Kwack DW; Kim DW
Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
[TBL] [Abstract][Full Text] [Related]
3. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
Larsen EP; Ostergaard JR
Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for hyperammonemia in pediatric patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
[TBL] [Abstract][Full Text] [Related]
5. Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study.
Woo PYM; Woo AWY; Lam SW; Ko NMW; Ho JWK; Chu ACH; Kwan MCL; Chan Y; Wong HT; Chan KY
World Neurosurg; 2020 Dec; 144():e597-e604. PubMed ID: 32916358
[TBL] [Abstract][Full Text] [Related]
6. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
[TBL] [Abstract][Full Text] [Related]
8. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
Cheng M; Tang X; Wen S; Yue J; Wang H
Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073
[TBL] [Abstract][Full Text] [Related]
9. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management.
Chopra A; Kolla BP; Mansukhani MP; Netzel P; Frye MA
Gen Hosp Psychiatry; 2012; 34(3):290-8. PubMed ID: 22305367
[TBL] [Abstract][Full Text] [Related]
10. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.
Vossler DG; Wilensky AJ; Cawthon DF; Kraemer DL; Ojemann LM; Caylor LM; Morgan JD
Epilepsia; 2002 Feb; 43(2):154-9. PubMed ID: 11903461
[TBL] [Abstract][Full Text] [Related]
11. Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report.
Liu X; Peng X
Neurol Sci; 2023 Oct; 44(10):3669-3673. PubMed ID: 37243793
[TBL] [Abstract][Full Text] [Related]
12. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
[TBL] [Abstract][Full Text] [Related]
13. Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid.
Smith KM; Britton JW; Hocker SE; Toledano M
Neurologist; 2021 May; 26(3):80-82. PubMed ID: 33942787
[TBL] [Abstract][Full Text] [Related]
14. Valproic Acid-Induced Hyperammonemic Encephalopathy in a Patient with Bipolar Disorder: A Case Report.
Wu MY; Chang FY; Ke JY; Chen CS; Lin PC; Wang TS
Brain Sci; 2020 Mar; 10(3):. PubMed ID: 32213827
[TBL] [Abstract][Full Text] [Related]
15. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
Mock CM; Schwetschenau KH
Am J Health Syst Pharm; 2012 Jan; 69(1):35-9. PubMed ID: 22180549
[TBL] [Abstract][Full Text] [Related]
16. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Hamed SA; Abdella MM
Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
[TBL] [Abstract][Full Text] [Related]
17. Gait instability in valproate-treated patients: Call to measure ammonia levels.
Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
[TBL] [Abstract][Full Text] [Related]
18. Valproate-induced hyperammonemic encephalopathy.
Verrotti A; Trotta D; Morgese G; Chiarelli F
Metab Brain Dis; 2002 Dec; 17(4):367-73. PubMed ID: 12602513
[TBL] [Abstract][Full Text] [Related]
19. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
[TBL] [Abstract][Full Text] [Related]
20. Hyperammonemia following intravenous valproate loading.
DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
